The AI Act: Progressing Faster Than Expected

The European Parliament is scheduled to vote on the legislation March 13, and one of the lawmakers leading the legislation said he expects it to pass easily. Under the current timeline the law would largely take effect in 2026, although some provisions would kick in this year.

The EU Parliament has rescheduled its vote to March 13, a full month sooner than originally planned. According to statements from Members of Parliament, the parliamentary vote is expected to closely mirror the committee's decision. The Act is anticipated to be approved by a significant majority of the members.

Next Steps: Following the Parliament's vote, the Council, consisting of governments from EU member states, will officially approve the Act. According to the present schedule, the law is set to come into full effect by 2026, though certain elements may be implemented as early as this year.

Overview of the Act:

  • The Act aims to categorize AI applications according to their risk level, imposing bans on specific applications such as "emotion recognition" in workplaces, which could lead to the highest penalties: either 7% of worldwide revenue or 35 million euros (approximately $38 million), whichever is greater.
  • The legislation will affect companies operating within the 27-country bloc and developers of AI systems used in the EU, regardless of their location, including those in the USA.
  • Any company that introduces a product to the EU market will need to comply with the AI Act, meaning its products must adhere to the regulations set forth by the Act.

Click here to read more

Seamus Larroque

CDPO / CPIM / ISO 27005 Certified


Discover our latest articles

View All Blog Posts
April 23, 2024
No items found.

iliomad is deligthed to have supported the ICM - Institut du Cancer de Montpellier in their CNIL's authorization process

We are delighted to share that the ICM - Institut du Cancer de Montpellier was authorized by the French Data Protection Authority (CNIL) to conduct APAD-ECO study. The CNIL granted authorization to conduct a medico-economic study on the effects of physical activity in women treated for breast cancer on April, 19th. This groundbreaking study involves combining data from two clinical trials with that of the Caisse nationale de l’Assurance Maladie, covering the period from 2009 to 2022. The study aims to assess the long-term impacts of physical activity in patients who have undergone treatment for breast cancer. We are proud to have contributed to this project by providing the ICM - Institut du Cancer de Montpellier with a compliant Data Protection Impact Assessment (DPIA), a crucial step in obtaining CNIL approval.